Eli Lilly is dropping a BACE inhibitor that was being tested in Alzheimer’s disease in combination with a second drug, a monoclonal antibody that binds to amyloid deposits in the brain. The news, ...
Johnson & Johnson’s Janssen unit has joined the far-from-exclusive Alzheimer's disease failure club after deciding to terminate trials of its BACE inhibitor atabacestat. This time the decision hasn’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback